GNPX Genprex Inc.: רווח למניה לשנה מתגלגלת

Genprex, Inc. (GNPX) is driving price action through the development of gene-based therapies for diabetes and lung cancer utilizing nanoparticles. The YoY change in EPS on a rolling 12-month basis confirms that the 93.90 mark serves as a key trend metric. This effect is further amplified by the ONCOPREX ecosystem with its closed patent loop and the full capacity utilization of R&D laboratories producing viral vectors.
GNPX (Genprex): פילוחים אנליטיים ודוחות לפי אינדיקטורים

This indicator measures the rolling year earnings per share (EPS) dynamics, allowing for an assessment of the company's financial trajectory stability while filtering out market noise. By analyzing the annual EPS growth rate over the last 12 months, an investor can correlate the effectiveness of Genprex, Inc. (GNPX) academic alliances in oncology with actual capital growth, taking into account the risks associated with early-stage clinical trials.